With over 30 years of expertise in developing highly specialized human skin models that can be kept in culture for several months, we offer an extensive range of platforms for cosmetic analyses. Our full-thickness models accurately replicate the structure and function of human skin, including the dermal compartment, enabling precise testing of cosmetic ingredients. From assessing the efficacy of anti-aging formulations on epidermal and dermal morphogenesis, to studying the interaction between ingredients and the microbiome. By simulating young and aged skin conditions, we can examine if the tested ingredients are safe, effective, and scientifically validated.
Gentiss offers advanced epidermal and full-thickness skin models tailored to meet the specific needs of the pharmaceutical industry. Our models replicate the structural and functional complexity of human skin, making them ideal for drug efficacy, safety, and mechanistic studies. We can also customize our models to your specific research needs. Whether it’s testing new topical formulations or understanding their effect on epidermal or dermal morphogenesis, our skin models provide reliable, reproducible data. Additionally, we offer in-depth biological analyses, such as cytokine profiling, to assess inflammatory responses, gene expression studies to explore molecular pathways, and protein analyses to evaluate drug-target interactions and pathway modulation. Gentiss human skin models streamline your development processes, reducing time-to-market while ensuring regulatory compliance and product safety.
Gentiss safety tests examine compound toxicity via skin corrosion and skin irritation according to standardized Organization for Economic Co-operation and Development (OECD) guidelines. We use a variety of test model types, including cell monocultures and in vitro skin models with competent barrier function, depending on your needs. Corrosive or irritant substances are identified by their ability to reduce cell viability below specific threshold levels, after defined exposure periods.
Since the late 1980s, our skin model technology has been used in over 400 academic research papers.
Most recent:
Wu S, Fang R, Rietveld MH, Torremans JRG, Liu Y, Gu Z, Bouwes Bavinck JN, Vermeer MH, El Ghalbzouri A. Identification of Small-Molecule Inhibitors Targeting Different Signaling Pathways in Cancer-Associated Fibroblast Reprogramming under Tumor-Stroma Interaction. J Invest Dermatol. 2024 Jun 5:S0022-202X(24)00392-0. doi: 10.1016/j.jid.2024.04.026. Epub ahead of print. PMID: 38848988.
Helder RWJ, Rousel J, Boiten WA, Gooris GS, Nadaban A, El Ghalbzouri A, Bouwstra JA. The effect of PPAR isoform (de)activation on the lipid composition in full-thickness skin models. Exp Dermatol. 2023 Apr;32(4):469-478. doi: 10.1111/exd.14733. Epub 2023 Jan 2. PMID: 36541108.
Niehues H, Bouwstra JA, El Ghalbzouri A, Brandner JM, Zeeuwen PLJM, van den Bogaard EH. 3D skin models for 3R research: The potential of 3D reconstructed skin models to study skin barrier function. Exp Dermatol. 2018 May;27(5):501-511. doi: 10.1111/exd.13531. Epub 2018 Apr 6. PMID: 29518287.
Bouwstra JA, Helder RWJ, El Ghalbzouri A. Human skin equivalents: Impaired barrier function in relation to the lipid and protein properties of the stratum corneum. Adv Drug Deliv Rev. 2021 Aug;175:113802. doi: 10.1016/j.addr.2021.05.012. Epub 2021 May 18. PMID: 34015420.
Barrier:
Helder RWJ, Rousel J, Boiten WA, Gooris GS, Nadaban A, El Ghalbzouri A, Bouwstra JA. Improved organotypic skin model with reduced quantity of monounsaturated ceramides by inhibiting stearoyl-CoA desaturase-1. Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Apr;1866(4):158885. doi: 10.1016/j.bbalip.2021.158885. Epub 2021 Jan 11. PMID: 33444760.
Mieremet A, Helder R, Nadaban A, Gooris G, Boiten W, El Ghalbzouri A, Bouwstra JA. Contribution of Palmitic Acid to Epidermal Morphogenesis and Lipid Barrier Formation in Human Skin Equivalents. Int J Mol Sci. 2019 Dec 2;20(23):6069. doi: 10.3390/ijms20236069. PMID: 31810180; PMCID: PMC6928966.
Mieremet A, Boiten W, van Dijk R, Gooris G, Overkleeft HS, Aerts JMFG, Bouwstra JA, El Ghalbzouri A. Unravelling effects of relative humidity on lipid barrier formation in human skin equivalents. Arch Dermatol Res. 2019 Nov;311(9):679-689. doi: 10.1007/s00403-019-01948-3. Epub 2019 Jul 18. PMID: 31321505; PMCID: PMC6787114.
Cancer:
He Y, Wu S, Rietveld M, Vermeer M, Cruz LJ, Eich C, El Ghalbzouri A. Application of Doxorubicin-loaded PLGA nanoparticles targeting both tumor cells and cancer-associated fibroblasts on 3D human skin equivalents mimicking melanoma and cutaneous squamous cell carcinoma. Biomater Adv. 2024 Jun;160:213831. doi: 10.1016/j.bioadv.2024.213831. Epub 2024 Mar 17. PMID: 38552501.
Wu S, Rietveld M, Hogervorst M, de Gruijl F, van der Burg S, Vermeer M, van Doorn R, Welters M, El Ghalbzouri A. Human Papillary and Reticular Fibroblasts Show Distinct Functions on Tumor Behavior in 3D-Organotypic Cultures Mimicking Melanoma and HNSCC. Int J Mol Sci. 2022 Oct 1;23(19):11651. doi: 10.3390/ijms231911651. PMID: 36232952; PMCID: PMC9570214.
Hogervorst M, Rietveld M, de Gruijl F, El Ghalbzouri A. A shift from papillary to reticular fibroblasts enables tumour-stroma interaction and invasion. Br J Cancer. 2018 Apr;118(8):1089-1097. doi: 10.1038/s41416-018-0024-y. Epub 2018 Mar 19. PMID: 29551776; PMCID: PMC5931114.
Aging:
Kleissl L, Weinmüllner R, Lämmermann I, Dingelmaier-Hovorka R, Jafarmadar M, El Ghalbzouri A, Stary G, Grillari J, Dellago H. PRPF19 modulates morphology and growth behavior in a cell culture model of human skin. Front Aging. 2023 May 5;4:1154005. doi: 10.3389/fragi.2023.1154005. PMID: 37214773; PMCID: PMC10196211.
Janson D, Rietveld M, Mahé C, Saintigny G, El Ghalbzouri A. Differential effect of extracellular matrix derived from papillary and reticular fibroblasts on epidermal development in vitro. Eur J Dermatol. 2017 Jun 1;27(3):237-246. doi: 10.1684/ejd.2017.2984. PMID: 28524059.
Janson D, Saintigny G, Zeypveld J, Mahé C, El Ghalbzouri A. TGF-β1 induces differentiation of papillary fibroblasts to reticular fibroblasts in monolayer culture but not in human skin equivalents. Eur J Dermatol. 2014 May-Jun;24(3):342-8. doi: 10.1684/ejd.2014.2312. PMID: 24721636.
Wound healing:
Raktoe R, Kwee AKAL, Rietveld M, Marsidi N, Genders R, Quint K, van Doorn R, van Zuijlen P, Ghalbzouri AEL. Mimicking fat grafting of fibrotic scars using 3D-organotypic skin cultures. Exp Dermatol. 2023 Oct;32(10):1752-1762. doi: 10.1111/exd.14893. Epub 2023 Jul 28. PMID: 37515391.
Raktoe RS, van Haasterecht L, Antonovaite N, Bartolini L, van Doorn R, van Zuijlen PPM, Groot ML, El Ghalbzouri A. The effect of TGFβRI inhibition on extracellular matrix structure and stiffness in hypertrophic scar-specific fibroblast-derived matrix models. Biochem Biophys Res Commun. 2021 Jun 25;559:245-251. doi: 10.1016/j.bbrc.2021.04.071. Epub 2021 May 5. PMID: 33964734.
Raktoe RS, Rietveld MH, Out-Luiting JJ, Kruithof-de Julio M, van Zuijlen PP, van Doorn R, Ghalbzouri AE. Exon skipping of TGFβRI affects signalling and ECM expression in hypertrophic scar-derived fibroblasts. Scars Burn Heal. 2020 May 28;6:2059513120908857. doi: 10.1177/2059513120908857. PMID: 32528734; PMCID: PMC7263111.